key: cord-0698219-r6i53kc1
authors: Wellens, Judith; Colombel, Jean-Frédéric; Satsangi, Jack J; Wong, Serre-Yu
title: SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges
date: 2021-03-15
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjab046
sha: ab191fb6e9ed8f29febc26ce5b9a4b0552e56f2b
doc_id: 698219
cord_uid: r6i53kc1

Since the beginning of the pandemic, patients with inflammatory bowel diseases (IBD) have been considered at high-risk for infection and complications of COVID-19. However, IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimize immunogenicity. We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.

The inflammatory bowel diseases (IBD), principally Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract of global importance, with prevalence rates of approximately 0.5-1% in Western populations. 1 The clinical management of IBD during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has been an area of great concern to patients and physicians worldwide. While IBD patients have altered underlying immune responses which may leave them more vulnerable to infections 2 , immunosuppressive treatment is widely accepted as a key determinant of risk for serious, opportunistic and vaccine preventable infections 3, 4 .

Of immediate concern given the recent roll-out of several vaccines to combat COVID-19 (Corona Virus Disease 2019), is the consideration that the immunological response to vaccination may be blunted in IBD patients receiving immunosuppressant treatment, increasing the need for alternative strategies. 3 IBD patients were not included in safety and efficacy phase III-trials for COVID-19 vaccines, and neither were patients managed with immunosuppressive therapies. In this review we aim to complement existing recommendations considering vaccination for SARS-CoV-2 in IBD patients by integrating knowledge of efficacy and safety of vaccines other than SARS-CoV-2 in IBD patients with the rapidly emerging data from vaccination and viral evolution in SARS-CoV-2. 5 by the nature of the therapy or paradoxically decreases it by addressing intestinal or systemic inflammation, is unclear. [6] [7] [8] As a result, early in the first wave of the pandemic, guidelines from the International Organization for the study of Inflammatory Bowel Disease (IOBD) were released suggesting that after an assessment of potential risks and benefits, maintenance therapies should not be withheld. 8 Furthermore, patients on immunomodulation were asked to adapt stringent hygienic measures, 'shielding' from the community if possible or put in place extended social distancing to avoid infection. 7, 9 The initial data that emerged regarding the risk of severe COVID-19 in IBD patients in 2020 were relatively reassuring. The first observational data reporting on this risk, came from Italian centers and reported no increased negative outcomes in IBD patients, even when on anti-TNF therapy. 10 The Surveillance Epidemiology showed that systemic corticosteroids, but not anti-TNF was associated with severe COVID-19. 11 However, more recently, the extended follow-up report from the SECURE-IBD of 1439 patients in 47 countries raised concern that thiopurine monotherapy and combination therapy of thiopurines and infliximab was associated with increased risk for severe COVID-19, compared to infliximab monotherapy.

Whilst the SECURE registry addressed the incidence of severe complications, the study has not allowed assessment of susceptibility to mild or subclinical infection. In this context, observational seroprevalence data from Germany, Italy, the UK, and US (private communication) in IBD patients on either vedolizumab or infliximab did not show an elevated seroprevalence of SARS-CoV-2, suggesting continuation of infusion medications and attending infusion centers are safe practices. 10, [12] [13] [14] [15] Indeed these data leave open the possibility of a protective effect of cytokine blockers. 12 It is important to note that these are observational studies and carry the risk of confounding bias. For example, more restrictive social behaviors might explain these results.

Several large prospective studies are currently under way to assess seroprevalence longitudinally in IBD patients treated with infusion therapies (vedolizumab and infliximab), namely the global International study of A c c e p t e d M a n u s c r i p t 5 COVID-19 Antibody Response Under Sustained immune suppression in IBD (ICARUS) 16 and the UK Impact of Biologic and Immunomodulatory Therapy on SARS-CoV-2 Infection and Immunity in Patients with Inflammatory Bowel Disease (CLARITY-IBD) initiatives (ISRCTN45176516). These studies will yield important information on IBD patients' immunological response to natural infection with SARS-CoV-2 and the effects of immunomodulating therapeutics, which are important baseline data as we look to assess responses to SARS-CoV-2 vaccines in these patients. When available, the data can be contrasted to our current knowledge of the pathophysiology and immune response associated with natural recovery in the immunocompetent host, as is discussed in section 4.1.

The pandemic has catalyzed a rapid joint response from research and industry to produce a novel vaccine. This has paved the way for the development of new vaccination strategies such as mRNA platforms and use of adenoviral vectors, of which there are now registered vaccines, while others are still in various stages of development ( figure 1 ). 17, 18 Most current vaccines target the spike protein of SARS-CoV-2, which is the protein that binds to the ACE2 receptor, since analysis of convalescent patients suggested that this is an immunodominant antigen, eliciting both antibody and T cell responses. 19 The ChAdOx1 nCoV-19 vaccine developed by AstraZeneca in Oxford, is a replication-defective chimpanzee adenovirus-vectored vaccine that expresses the full-length SARS-CoV-2 spike glycoprotein gene. The advantage of the adenovirus vector is that viral antigens can be transferred safely to host cells without the risk of replication (of living viral vaccines) and without the need for adjuvants, but with preserved induction of strong T cell responses 20 . A simian adenovirus was used to bypass potential pre-existing immunity to the vector. This vaccine was indeed shown to induce both humoral and T cell responses in rhesus macaques and humans. 18, 21 .

In their phase I/II trials, Barrett and colleagues showed that the vaccine elicited a multifunctional antibody response, with the formation of Fc-mediated antibody responses (such as antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation), along with neutralizing antibodies to the spike protein (figure 2). 22 In the interim analysis of their phase III trial (4 RCTs in Delivered with a 21-day interval, an interim phase III trial analysis showed an efficacy of 91.6% (COVID-19

confirmed cases) with good tolerability. 25 In addition, there are currently two types of mRNA vaccines available: the 1273 and BNT162b2 vaccine by 

A statement from the IOBD was recently released; using the Delphi method, the group's consensus clearly states that vaccination is safe and the ideal timing for vaccination is as early as possible. 32 Concurring with this, both D' Amico et al and the British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement proclaim that the advantages to vaccination outweigh the possible disadvantages from vaccinating our patients and that unbiased and consistent advice should be provided to patients to discourage vaccine hesitancy. 5, 33 Moreover, all cited sources emphasize that vaccine effectiveness rather than safety is the key concern in IBD patients, and patients should be encouraged to receive vaccination whenever possible to reach the highest possible vaccination rate. 

Although numerous groups and experts support the importance of adequate vaccination of IBD patients 34, 35 , the percentage of physicians that monitor and routinely recommend vaccination to IBD patients is low (approximately 50%) 2, 4 , resulting in a lower vaccination uptake in IBD patients compared to the general population. 4, 36 Importantly, vaccination in IBD is considered to be safe and is not associated with disease onset A c c e p t e d M a n u s c r i p t 8 or exacerbation. 32,33 Studies assessing the inherent immunogenicity of vaccination strategies in IBD are scarce and mainly date back to a time when treatment options were limited (table 1) . However, the therapeutic armamentarium that is available today comprises a variety of immunomodulatory drugs, which may be important determinants of altered immunogenicity to vaccination efforts (table 2-3) .

Regarding influenza vaccination, several studies have suggested attenuated responses in IBD patients. A study of 132 IBD patients reported adequate immunogenicity with lower response to the inactivated quadrivalent influenza vaccine when treated with infliximab. 37 Furthermore, a prospective study in 255 IBD patients confirmed high seroprotection rates, but with lower persistence in patients with anti-TNF treatment. 38 This was confirmed again in a study with 66 IBD patients that showed inhibited response to some strains when under infliximab, immunomodulators or the combination of both. 39 Yet another study on the adjuvanted 2009 A/H1N1 pandemic vaccine showed that patients on infliximab had a worse serological response than healthy controls, and worse still when treated with a combination of infliximab and other immunosuppressive therapy. 40 On the other hand, in a large rheumatological study, adequate serological protection was found after a single influenza vaccination, without significant effect of TNF-blockers. 41 A similar study that included IBD patients also showed that the proportion of patients attaining a protective response was not significantly altered (although a modest decrease in antibody response to A/H3N2 and B was noted), suggesting vaccination in these patients is productive. 42 Looking at non-influenza vaccines, the hepatitis B vaccine has been extensively studied and has been found to be less immunogenic in IBD patients than in non-IBD controls, which is even more pronounced when treated with immunosuppressant medication. 4 Mechanistically, recent research in patient with ankylosing spondylitis has revealed that TNF blockade severely inhibits T cell dependent humoral responses, resulting in suppressed responses to hepatitis B vaccination. On the other hand, T cell independent response to the 23-valent A c c e p t e d M a n u s c r i p t 9 pneumococcal polysaccharide vaccine (PPSV-23) was only modestly affected. 43 Interestingly, a study of 15 CD patients showed that clinical response to infliximab was associated with an improvement of splenic function measured by a decreased proportion of pitted red cells and expansion of the IgM-memory B cell pool. This memory B cell population is important for protection against encapsulated bacteria, illustrating the complexity of vaccination responses. 44 Regarding new vaccination platforms, one study regarding adenoviral vector vaccines in vitro has shown that mucosal-associated invariant T (MAIT) cells contribute to maximal immunogenicity in a TNF-dependent manner in both mice and humans. 45 This raises the concern that there may be reduced protection conferred via adenoviral-based vaccines, when receiving anti-TNF based, maintenance therapy. Moreover, the functionality of MAIT cells in mounting and effective immune response in IBD patients without TNF blockers, needs to be determined. While only recently discovered in 1993, MAIT cells represent about 10% of our T cell population and are profusely found in peripheral blood, liver, gut and lungs.

They perform innate-like immunity functions upon recognition of bacterial metabolites through an MHC-class I-related MR-I molecule or through T cell receptor-independent activation via inflammatory and antiviral cytokines to combat viral infection and have both (tissue specific) effector and memory functions, which are attractive for vaccine development for pathogens that propagate through mucosal entry. 46 In IBD patients, MAIT cells in the peripheral blood are found to be reduced, but exert a more activated state, while data on MAIT cells in inflamed gut tissue are conflicting. 47 What this means for vaccination response in IBD patients, is currently unknown.

These studies raise the concern that patients receiving immunosuppressive therapies like anti-TNF (combination therapy) may be at risk for reduced vaccination responses. The question is: can attenuated vaccine responses be overcome in IBD patients? Strategies to address this for other vaccines have involved alternate dosing and schedules. The aforementioned study of 132 patients, showed no effect for an added booster of the quadrivalent inactivated influenza virus. 37 These results are similar to an earlier randomized study on the trivalent influenza vaccine, also reporting that a second booster did not improve the immune response in 78 IBD patients treated with immunosuppressant therapy. 48 A c c e p t e d M a n u s c r i p t 10 Alternatively, a higher dosage protocol could be considered. A randomized controlled trial in 59 IBD patients (40 on infliximab and 19 on vedolizumab) and 20 healthy controls, generated significantly higher H3N2 antibody levels when receiving the high dose vaccine compared with the standard dose. 49 In contrast, H1N1 postimmunization antibody levels were not significantly different. Interestingly, IBD patients receiving the high dose influenza vaccine and those on vedolizumab who received standard dose had equivalent antibody concentrations to healthy controls. Taken together, these data suggest that higher dose influenza vaccines could be beneficial in patients on anti-TNFs but not needed in patients receiving vedolizumab. 49 Regarding hepatitis B vaccination, a significantly higher seroconversion rate was found in 148 Crohn's disease patients (with or without immunosuppressive therapy) after adapting a double dosage and faster protocol (Engerix B double dose at 0, 1 and 2 months vs. the standard protocol (Engerix-B single dose at 0, 1 and 6 months). 50 Of note, considering the timing of infusion relative to administration of a vaccine, a randomized controlled trial in influenza in 137 IBD patients on infliximab maintenance therapy showed no difference in serological protection whether the vaccine was administered midway or at the time of infusion. 51 There is limited evidence on vaccination efficacy for the newer therapies such as vedolizumab, ustekinumab and tofacitinib. Nonetheless, the current evidence available for these therapies is generally encouraging. 52, 53 Interestingly, IBD patients receiving ustekinumab appear to mount robust humoral and T cell responses to influenza vaccination. 54 On the other hand, there may be reduced responses to oral vaccination strategies in patients on vedolizumab, possibly due to reduced homing of T cells, assessed after administering an oral cholera vaccine. 55 As we look to other diseases for which these medications are prescribed, in rheumatoid arthritis patients, tofacitinib is associated with a reduced humoral response to the PPSV23 vaccine (pneumococcal polysaccharide vaccine). 56, 57 Notably, ustekinumab is also used in psoriasis, but with a different dosing regimen than when treating colitis, thus complicating comparison. 58 A c c e p t e d M a n u s c r i p t 11

As SARS-CoV-2 vaccine distribution broadens, patients and clinicians will be first and foremost eager to know clinical efficacy of vaccination in IBD patients. In addition to this, it is crucial to note that immune protection To complicate this analysis of response further, "adequate" levels of binding antibodies do not necessarily mean they are also functional in terms of neutralization capacity for viruses. 59, 61 In fact, antibody response in vitro does not necessarily correlate with health outcomes. It is important to note that seroconversion does not translate into disease protection, and the correlate can also be true -a lack of seroconversion is not necessarily associated with susceptibility. 59, 65 In addition, antibody levels may wane with time, but seronegative individuals can still be protected through other immune mechanisms, as shown, after hepatitis B vaccination. 59 Thus, while measuring antibodies is straightforward, interpretation of results can be rather complex.

Furthermore, there is good evidence to support the role of cellular immunity in combatting SARS-CoV-2.

antibody response, cytotoxic capacities and inducing a long term immunological memory to protect against reinfection, even with cross-reactive properties. 68 These will be important to explore in IBD patients, for which little is known regarding T cell responses to SARS-CoV-2. Evidence from cytomegalovirus (CMV) suggests passive antibodies have the ability to protect, but once latent infection has been established, T cell function is necessary to control reactivation and clinical disease. 61 In the case of influenza, antibody titers after vaccination are shown to be unreliable for predicting risk of influenza in the elderly, again necessitating a T cell response. 20 Assays that measure B and T cell activation, lymphoproliferation, and cytokine responses to SARS-CoV-2 in IBD patients are needed, as well as standards for the general population and more 'classic' virology for comparison.

As an added factor, the genetic profile may be important in the vaccinee, and several HLA haplotypes in the general population have been associated with a higher risk of vaccination failure; however, whether these genetic factors cause deficient antigen presentation or diminished recognition by immune cells and whether this will be important in SARS-CoV-2 remains unknown. 2 Large ongoing genomics research efforts will be informative, as they have been in identifying determinants of severe COVID-19.

A c c e p t e d M a n u s c r i p t 13 Finally, immune development could be influenced by SARS-CoV-2 infection in the gut, which is of particular importance in IBD patients. COVID-19 appears to be associated with gut dysbiosis that can reflect disease severity and persist after viral clearance. 69 Intriguingly, memory B cells appear to undergo continued clonal turnover and somatic hypermutation six months after resolution of primary SARS-CoV-2 infection. 70 While yet to be proven as the causative persistent antigen presence driving long term enhancement of B cell responses, SARS-CoV-2 RNA was found in intestinal tissue biopsies from asymptomatic convalescent patients in whom nasopharyngeal swab PCRs were negative. 70 Taken together, in order to improve vaccine immunogenicity and efficacy, studies quantifying immune responses and individual determinants for response to vaccination in IBD patients will be essential to pursue. 59 

Recently, the topic of viral mutation was brought to the attention of both the lay press and the scientific community due to the emergence of several SARS-CoV-2 variants, broadly known as the 'UK', 'South-African'

and 'Brazilian' variant. [71] [72] [73] Interestingly, these kind of mutants were long expected, and there are currently more than 35,000 genome sequences publicly available with an ever-growing number. 74 As reported by the weaker neutralization responses to the B.1.1351-spike virus, which is of concern and warrants further study. 79, 80 Of recent special interest, is the E484K mutation, that has now not only been found in the 'South African' and 'Brazilian' variant, but has also emerged in UK samples. 81 Concern has arisen since Collier and colleagues released a preprint that assessed the immune response after BNT162b2 vaccination using a viral pseudotypes. 82 After a single vaccination, the neutralizing serum capacity was reduced by a 3.85-fold when comparing the wild-type to the B.1.1.7 containing pseudoviruses. This reduction was even more severe when an E484K mutation was introduced to the B. , though it is possible that non-neutralizing antibody functions or cellular immunity respond differently to these mutated variants and that the herd immunity after natural infection or vaccination is not affected in a dramatic way. Additionaly, increasing data show that the B.1.1.7 lineage might be associated with an increased risk of hospitalization and death as communicated by the New and Emerging

Respiratory Virus Threats Advisory Group (NERVTAG). 85 Viral surveillance is and will remain of utmost importance to diagnose potentially important mutations associated with increased infectivity or a more severe course of disease. Large-scale post-marketing (epidemiological) studies, integrated with these point-mutations and crystal structures will be key to understanding the true clinical meaning of this viral evolution. 86 A c c e p t e d M a n u s c r i p t Although overall the real-life evidence is increasingly encouraging, longer-term follow-up will be crucial in determining how these data translate to clinical outcomes. To date, alterations in immunity after 34 days after a first dose has not been reported formally and these findings might still alter these preliminary results. 93 A c c e p t e d M a n u s c r i p t 94 In light of these current trends, it will be of utmost important to follow vaccine responses carefully in IBD patients particularly as their responses to SARS-CoV-2 vaccination whether to standard or delayed dosing are unknown. 92 

The mechanisms involved in the altered response to vaccines in IBD patients remain largely unknown. Since A c c e p t e d M a n u s c r i p t

In preparation of this manuscript, no external funding was received.

No new data were generated or analyzed in support of this research. A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Made with Biorender.com.

Vaccine Proposed mechanism of reduced response Reference Pneumococcus (PPSV23) Impaired formation of memory B cells Di Sabatino et al. 9544 Fallahi et al. 96 Tetanus toxin Impaired generation of IgG secreting plasma cells Stevens et al. 97 HBV Not described Altunöz et al. 98 Belle et al. 99 Mumps Partial impairment in T cell response Tönnesmann et al. 100

A c c e p t e d M a n u s c r i p t 

Immunopathogenesis of IBD: Current state of the art

Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease

Optimizing Immunization Strategies in Patients with IBD

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses

SARS-CoV-2 vaccination for patients with inflammatory bowel disease : a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease

Management of IBD during the COVID-19 outbreak: resetting clinical priorities

Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

COVID-19 and immunomodulation in IBD

Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study

IBD in the COVID-19 era: the value of international collaboration

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 ( AZD1222 ) vaccine : a pooled analysis of four randomised trials

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Vaccination in inflammatory bowel disease patients: Attitudes, Knowledge, and Uptake

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy

Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study

Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study

The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination

Anti-TNF treatment blocks the induction of T cell-dependent humoral responses

Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab

MAIT cell activation augments adenovirus vector vaccine immunogenicity

MAIT cells as attractive vaccine targets

Mucosal-associated invariant T cells in autoimmune and immune-mediated diseases

Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial

Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease

Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial

Optimizing Immunization Strategies in Patients with IBD

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

High immunogenicity to influenza vaccination in crohn's disease patients treated with ustekinumab

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use

Factors That Influence the Immune Response to Vaccination

Immunogenetics of seasonal influenza vaccine response

Correlates of vaccine-induced immunity

Phase 1-2 Trial of a SARS

Recombinant Spike Protein Nanoparticle Vaccine

Correlates of protection against SARS-CoV-2 in rhesus macaques

Monoclonal Antibodies for Prevention and Treatment ofCOVID-19

The optimal age of measles immunisation in low-income countries: A secondary analysis of the assumptions underlying the current policy

Immunological memory and protective immunity: Understanding their relation

From Vaccines to Memory and Back

Cellular immune responses to covid-19

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Evolution of antibody immunity to SARS-CoV-2

Doi: rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Alice Sampaio Rocha1, Alex Pauvo MMS. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Center for disease control U. Emerging SARS-CoV-2 variants

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants

SARS-CoV-2 501Y . V2 escapes neutralization by South African COVID-19 donor plasma

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine -Preliminary Report

Neutralizing Activity of BNT162b2-Elicited Serum -Preliminary Report

Covid-19: The E484K mutation and the risks it poses

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

NERVTAG: Update note on B.1.1.7 severity

61042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf

Comment Public health surveillance of infectious diseases : beyond point mutations

Covid-19 vaccines: to delay or not to delay second doses

Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland : national prospective cohort study of 5.4 million people

Are COVID vaccination programmes working? Scientists seek first clues

Early rate reductions of and COVID-19 in BNT162b2 vaccine recipients

Durability of Responses after SARS-CoV-2 mRNA-1273

Revisiting the UK's strategy for delaying the second dose of the Pfizer covid-19 vaccine

Covid-19 : First doses of vaccines in Scotland led to a substantial fall in hospital admissions

Covid-19: Doctors in Norway told to assess severely frail patients for vaccination

Immunoglobulin M memory B cell decrease in inflammatory bowel disease

Evaluation of antibody response to polysaccharide vaccine and switched memory B Cells in pediatric patients with inflammatory bowel disease

Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients

Patients with inflammatory bowel disease have

a lower response rate to HBV vaccination compared to controls

Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases

The immune competence of patients with Crohn's disease

Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease

Immune response to influenza vaccine in children with inflammatory bowel disease

Immune Response to Influenza Vaccine in Pediatric Patients With Inflammatory Bowel Disease

Efficacy of hepatitis b vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease

Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients

Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter 30 study

Seroconversion analysis after habitual hepatitis B vaccination scheme in patients with inflammatory bowel diseases

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab. Crohn's

Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study

Efficacy of hepatitis a vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease

Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines

We would like to acknowledge the support from the Leona M. and Harry B. Helmsley Charitable Trust and Siemens to make the ICARUS study possible.

All authors listed have made a substantial, direct and intellectual contribution to the paper and approved it for publication.

A c c e p t e d M a n u s c r i p t DeBruyn et al. 101 Lu et al. 102 Doornekamp et al. 54 103 Mamula et al. 103 Andrisani et al. 40 Hagihara et al. 39 Gelinck et al. 42 Shirai et al. 37 Launay et al. 38 HBV Anti-TNF, thiopurines, combination therapy anti-TNF and thiopurines, 'Immunosuppression' defined as systemic corticosteroid or biologic therapy or thiopurines or combination therapy Gisbert et al. 104 Chaparro et al. 105 Loras et al. 106 Altunöz et al. 98 Cunha et al. 107 Andrade et al. 108 Harrington et al. 109 Pneumococcus (PPSV 23) Anti-TNF, combination therapy anti-TNF and thiopurines. Melmed et al. 110 Fiorino et al. 111 HAV Anti-TNF therapy Park et al. 112 Oral cholera vaccine Vedolizumab Wyant et al. 55

A c c e p t e d M a n u s c r i p t